苏维西塔单抗为重组人源化抗VEGF单克隆抗体，其通过差异化分子表位设计精准阻断VEGF通路。临 床前研究显示，其对VEGF与其受体结合的抑制能力强于同类单抗，在模型中表现出更显著的抗血管生 成和抗肿瘤效果。 凭借卓越的临床数据，美国国家综合癌症网络2025年11月发布的《NCCN卵巢癌临床实践指南-中国 版》已将苏维西塔单抗列为铂耐药复发卵巢癌治疗首选方案，并获得国内多部权威指南的Ⅰ类或强推 荐，成为该治疗领域的新标准。 塞纳帕利是由英派药业自主研发的新型、高效的PARP1/2抑制剂，具有独特的分子结构，使其具备体外 和体内高活性，以及高靶向选择性和广泛的安全窗口。其III期注册性研究FLAMES Study结果显示，塞 纳帕利维持治疗能够显著延长晚期卵巢癌患者的中位无进展生存期（mPFS），而且无论患者是否伴有 乳腺癌易感基因（BRCA）突变，均能从塞纳帕利治疗中获益。同时，塞纳帕利耐受性良好，安全性可 控。该研究数据已于2024年5月发表于国际顶级医学期刊《Nature Medicine》。 日前，国家医疗保障局发布《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（国家医 保药品目录）《商业 ...

Market Overview - On December 8, the Hang Seng Index fell below the 26,000-point mark, closing down 319 points (1.2%) at 25,765 points, with a total market turnover of HKD 206.2 billion[1] - The market is awaiting the Federal Reserve's interest rate decision, with expectations of a 0.25% rate cut[1] - The net inflow of Hong Kong Stock Connect was HKD 1.54 billion[1] Sector Performance - Chinese brokerage stocks rose after the China Securities Regulatory Commission announced a slight easing of regulations, with Huatai Securities up 5.2%, China Merchants Securities up 2.8%, and CITIC Securities up 1.7%[1] - Major Chinese banks saw declines, with China Construction Bank down 4.0%, China Merchants Bank down 3.5%, and Industrial and Commercial Bank of China down 3.5%[1] - Pop Mart's stock dropped 8.5% amid concerns over declining sales growth for Labubu products[1] U.S. Market Insights - The Dow Jones Index closed down 215 points (0.4%) at 47,739 points, while the Nasdaq fell 32 points (0.1%) to 23,545 points, and the S&P 500 dropped 23 points to 6,846 points[2] - Investors expect the Federal Reserve to cut rates by 0.25% on Thursday, supported by a milder core PCE index[2] Macroeconomic Data - China's total import and export value in November was USD 549.03 billion, up 4.3% year-on-year, with exports rising 5.9% and imports increasing by 1.9%[3] - The trade surplus was USD 111.68 billion, exceeding market expectations of USD 103.1 billion[3] - In the real estate sector, new home sales in 30 major cities fell 33.3% year-on-year, with significant declines across all city tiers[3] Industry Trends - The automotive sector anticipates increased lithium battery production in December, leading to improved industry conditions and price increases, with CATL up 3.3% and Ganfeng Lithium up 7.0%[4] - The healthcare sector saw a 1.5% decline in the Hang Seng Healthcare Index, despite the addition of 114 new drugs to the national medical insurance list, benefiting several major pharmaceutical companies[4] - The renewable energy and utility sectors experienced declines, with major utility stocks falling between 1.0% and 2.8%[5]